Vol 82, No 2 (2024)
Original article
Published online: 2024-02-02

open access

Page views 214
Article views/downloads 83
Get Citation

Connect on Social Media

Connect on Social Media

First-year follow-up costs of myocardial infarction management in Poland from the payer’s perspective

Anna Skowrońska1, Siamala Sinnadurai23, Paweł Teisseyre145, Patrycja Gryka1, Agnieszka Doryńska1, Magdalena Dzierwa1, Mariusz Gąsior6, Marcin Grabowski7, Karol Kamiński3, Jarosław D Kasprzak8, Jacek Kubica9, Maciej Lesiak10, Bartosz Szafran11, Mariusz Wójcik12, Jarosław Pinkas13, Radosław Sierpiński14, Ryszard Gellert15, Piotr Jankowski216
DOI: 10.33963/v.phj.99006
Pubmed: 38348614
Pol Heart J 2024;82(2):183-191.


Background: Myocardial infarction (MI) remains a major burden for healthcare systems. Therefore, we intended to analyze the determinants of cost management of patients hospitalized for MI in Poland.
Methods: Data on patients hospitalized and discharged with the diagnosis of acute MI were derived from the public payer claims database. Adult patients, reported between October 1, 2017 and December 31, 2019, were included. Costs of hospitalization for acute MI and cumulative one-year follow-up were analyzed.
Results: The median (IQR) of the total direct cost was €3804.7 (2674.1–5712.7) per patient and 29% (€1113.6 [380.5–2490.4]) of these were costs related to the use of post-hospitalization healthcare resources. The median cost of cardiovascular disease management was €3624.7 (2582.1–5258.5), and 26% of this sum were follow-up costs. The analysis of the total cost for individual years showed a slight increase in median costs in subsequent years: €3450.7 (2407.8–5205.2) in 2017, €3753.8 (2642.6–5681.9) in 2018, and €3944.9 (2794.8–5844.4) in 2019. Male sex, heart failure, atrial fibrillation, diabetes, kidney disease, chronic obstructive pulmonary disease, and history of stroke in addition to hospitalization in a department other than cardiology or internal disease were independently related to the cost of MI patient management.
Conclusions: The high cost of management of MI patients was independently related to sex, heart failure, atrial fibrillation, diabetes, kidney disease, chronic obstructive pulmonary disease, and history of stroke as well as hospitalization in other than cardiology or internal disease department.

Article available in PDF format

View PDF Download PDF file


  1. Thompson SC, Nedkoff L, Katzenellenbogen J, et al. Challenges in managing acute cardiovascular diseases and follow up care in rural areas: a narrative review. Int J Environ Res Public Health. 2019; 16(24).
  2. Alipour V, Zandian H, Yazdi-Feyzabadi V, et al. Economic burden of cardiovascular diseases before and after Iran's health transformation plan: evidence from a referral hospital of Iran. Cost Eff Resour Alloc. 2021; 19(1): 1.
  3. Kannel WB. Incidence, prevalence, and mortality of cardiovascular diseases. In: Hurst’s the heart. 1994.
  4. Kumar A, Siddharth V, Singh SI, et al. Cost analysis of treating cardiovascular diseases in a super-specialty hospital. PLoS One. 2022; 17(1): e0262190.
  5. Jankowski P, Topór-Mądry R, Gąsior M, et al. Management and predictors of clinical events in 75 686 patients with acute myocardial infarction. Kardiol Pol. 2022; 80(4): 468–475.
  6. Kupisz-Urbańska M, Jankowski P, Topór-Mądry R, et al. Survival in nonagenarians with acute myocardial infarction in 2014-2020: A nationwide analysis. Kardiol Pol. 2023; 81(10): 1015–1017.
  7. Jankowski P, Topór-Mądry R, Gąsior M, et al. Innovative managed care may be related to improved prognosis for acute myocardial infarction survivors. Circ Cardiovasc Qual Outcomes. 2021; 14(8): e007800.
  8. Czech M, Opolski G, Zdrojewski T, et al. The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol. 2013; 71(3): 224–232.
  9. Sović N, Pająk A, Jankowski P, et al. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project. Kardiol Pol. 2013; 71(7): 702–711.
  10. Suwalski P, Kowalewski M, Jasiński M, et al. KROK Investigators. Survival after surgical ablation for atrial fibrillation in mitral valve surgery: Analysis from the Polish National Registry of Cardiac Surgery Procedures (KROK). J Thorac Cardiovasc Surg. 2019; 157(3): 1007–1018.e4.
  11. Plakht Y, Gilutz H, Arbelle JE, et al. Healthcare-service utilization and direct costs throughout ten years following acute myocardial infarction: Soroka Acute Myocardial Infarction II (SAMI II) project. Curr Med Res Opin. 2019; 35(7): 1257–1263.
  12. Steen Carlsson K, Nilsson K, Wolden ML, et al. Economic burden of atherosclerotic cardiovascular disease: a matched case-control study in more than 450,000 Swedish individuals. BMC Cardiovasc Disord. 2023; 23(1): 483.
  13. Cazzola M, Rogliani P, Ora J, et al. Asthma and comorbidities: recent advances. Pol Arch Intern Med. 2022; 132(4).
  14. Bonetto S, Fagoonee S, Battaglia E, et al. Recent advances in the treatment of irritable bowel syndrome. Pol Arch Intern Med. 2021; 131(7–8): 709–715.
  15. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med. 1991; 325(4): 221–225.
  16. Sinnadurai S, Sowa P, Jankowski P, et al. Recollection of physician information about risk factor and lifestyle changes in chronic coronary syndrome patients. Int J Environ Res Public Health. 2022; 19(11).
  17. Holstenson E, Ringborg A, Lindgren P, et al. Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace. 2011; 13(1): 23–30.
  18. Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014-2020). Pharmacoeconomics. 2020; 38(11): 1219–1236.

Polish Heart Journal (Kardiologia Polska)